Tags: new | sleeping | pill | reduces | side | effects | grogginess

New Sleeping Pill Has Fewer Side Effects

Friday, 20 Jul 2012 12:12 PM


The road to a sleeping pill that offers the snooze-inducing benefits of Ambien and Lunesta, while avoiding next-day grogginess and disorientation, has been paved with failure. Now, Merck & Co. may have found a solution.
In a study sponsored by Merck, patients on the company’s suvorexant performed better at a driving test the next day, staying in their lane more than patients on eszopiclone, the generic name for Lunesta.
The drugmaker is in final testing on an insomnia product, named suvorexant, that works differently than the market leaders. It blocks a tiny group of receptors that keep the body alert, rather than boosting the brain’s complex sleep system. The target is more precise, offering less room for side effects to occur, the Whitehouse Station, New Jersey-based company said. The pill, which would be the first of its class if approved by the FDA, could also allow people to use the treatments over longer periods.
“It’s not whether you put the patient to sleep or not, it’s how you feel the next day,” said Rafael Pelayo, a professor at Stanford School of Medicine’s Division of Sleep Medicine, in a telephone interview.
About 70 million, or one-third of American adults, have trouble falling or staying asleep, according to the American Psychiatric Association. Pelayo predicts that sleep issues will grow with the stress of modern life and the disruption from ever-present personal electronic devices, such as Apple Inc.’s iPhone, boosting the market for insomnia treatments.
Recent Failures
History, though, isn’t on Merck’s side. London-based Glaxo last year ended development of its leading sleep drug, almorexant. The problem: patients couldn’t tolerate its side effects.
Sanofi (SAN)’s bid to replace its own Ambien, which faced generic competition for the first time in 2006, ended when the Paris-based drugmaker failed to get U.S. approval for the treatment, called Ciltyri, in 2009.
Meanwhile, the two insomnia drugs that have been marketed since Ambien and Lunesta have failed to take hold with consumers.
Disappointed Clinicians
The newer therapies failed because they’ve haven’t reduced side effects, disappointing clinicians eager for new medicines, said Stanford’s Pelayo.
“People said, ‘Here’s the next big thing,’ and they turned out to be duds,” he said. Along with grogginess and driving troubles, Ambien can have side effects including stomach upset, diarrhea, nausea and headaches.
The failures have helped clear the field for Merck’s suvorexant, part of a potential new class of drugs known as orexin receptor antagonists.
The medicines may provide the same or better effectiveness against insomnia with fewer side effects, said Thomas Roth, director of the Sleep Disorders and Research Center at Henry Ford Health System in Detroit, by telephone.
“The therapy of insomnia has changed from trying to augment the power of the sleep system to trying to inhibit the wake system,” Roth said, explaining that orexins are a more focused target than the older class of drugs, including Ambien and Lunesta, barbiturates and benzodiazepines.
GABA Agonists
Those medicines called GABA agonists target billions of neuron receptors, affecting a wide range of body activities to achieve their goals. For instance, the therapies can be used as muscle relaxants and anesthetics, along with treating anxiety and convulsion, said Darryle Schoepp, Merck’s head of neuroscience development.
Orexin receptors targeted by the Merck drug are far fewer, with tens of thousands located in the brain’s hypothalamus. That makes for a more focused drug, Schoepp said.
Merck’s drug is the only one of the new class in the final of three stages of clinical trials usually required for regulatory approval.
Copyright Bloomberg News









© HealthDay

   
1Like our page
2Share
Health-News
A new sleeping pill appears to reduce the grogginess and disorientation that many patients have the following day.
new,sleeping,pill,reduces,side,effects,grogginess,disorientation,suvorexant,driving,test
588
2012-12-20
Friday, 20 Jul 2012 12:12 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved